Pangenomic Health Inc.
NARA
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -35.47% | 181.67% | 105.92% | 29.44% | -15.94% |
| Gross Profit | 35.47% | -181.67% | -105.92% | -29.44% | 15.94% |
| SG&A Expenses | 415.58% | 158.36% | -20.89% | -55.05% | -70.44% |
| Depreciation & Amortization | -93.55% | -95.24% | -80.43% | -56.52% | -31.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 182.48% | 157.40% | 12.65% | -34.36% | -60.01% |
| Operating Income | -182.48% | -157.40% | -12.65% | 34.36% | 60.01% |
| Income Before Tax | 10.77% | 4.73% | 51.75% | -82.30% | -25.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.77% | 4.73% | 51.75% | -82.30% | -25.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.77% | 4.73% | 51.75% | -82.30% | -25.68% |
| EBIT | -182.48% | -157.40% | -12.65% | 34.36% | 60.01% |
| EBITDA | -184.65% | -160.06% | -13.57% | 34.22% | 60.14% |
| EPS Basic | 69.57% | 59.74% | 74.39% | 35.70% | 50.77% |
| Normalized Basic EPS | 21.37% | 34.63% | 65.65% | 78.16% | 81.19% |
| EPS Diluted | 69.34% | 59.36% | 74.07% | 35.40% | 50.56% |
| Normalized Diluted EPS | 21.37% | 34.63% | 65.65% | 78.16% | 81.19% |
| Average Basic Shares Outstanding | 221.31% | 160.91% | 180.82% | 202.96% | 143.55% |
| Average Diluted Shares Outstanding | 221.31% | 160.91% | 180.82% | 202.96% | 143.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |